Moreover, a subgroup of AHSCT-treated patients exhibited a prolonged remission and remained insulin independent for more than 4 years, thus leading to hypothesize that the response to the AHSCT treatment may differ in patients with T1D (17, 35, 42). This evidence concerns the gene INS and type 1 diabetes mellitus.